1. Food and Drug Administration. Cancer drug and biological products—Clinical data in marketing applications. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-drug-and-biological-products-clinical-data-marketing-applications. Accessed 21 December 2021.
2. Sekine N, Aruga A. Selective safety data collection in clinical studies of oncology drugs for marketing approval in the United States. J Regul Sci. 2017;5(2):36–44.
3. Food and Drug Administration. A determining the extent of safety data collection needed in late-stage premarket and postapproval clinical investigations. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-extent-safety-data-collection-needed-late-stage-premarket-and-postapproval-clinical. Accessed 21 December 2021.
4. ICH E19 Guideline optimisation of safety data collection. Draft version endorsed on 3 April 2019. Step 2. https://database.ich.org/sites/default/files/E19_EWG_Draft_Guideline.pdf. Accessed 21 December 2021.
5. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–201.